- Home
- VANI vs CRBP Comparison
VANI vs CRBP Comparison
Compare VANI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- CRBP
- Stock Information
- Founded
- VANI 1998
- CRBP 2009
- Country
- VANI United States
- CRBP United States
- Employees
- VANI N/A
- CRBP N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- CRBP Health Care
- Exchange
- VANI Nasdaq
- CRBP Nasdaq
- Market Cap
- VANI 65.2M
- CRBP 73.4M
- IPO Year
- VANI 2014
- CRBP N/A
- Fundamental
- Price
- VANI $1.07
- CRBP $5.31
- Analyst Decision
- VANI Strong Buy
- CRBP Strong Buy
- Analyst Count
- VANI 1
- CRBP 10
- Target Price
- VANI $4.00
- CRBP $60.89
- AVG Volume (30 Days)
- VANI 102.7K
- CRBP 213.2K
- Earning Date
- VANI 03-31-2025
- CRBP 03-11-2025
- Dividend Yield
- VANI N/A
- CRBP N/A
- EPS Growth
- VANI N/A
- CRBP N/A
- EPS
- VANI N/A
- CRBP N/A
- Revenue
- VANI N/A
- CRBP N/A
- Revenue This Year
- VANI N/A
- CRBP N/A
- Revenue Next Year
- VANI N/A
- CRBP $270.01
- P/E Ratio
- VANI N/A
- CRBP N/A
- Revenue Growth
- VANI N/A
- CRBP N/A
- 52 Week Low
- VANI $1.03
- CRBP $5.12
- 52 Week High
- VANI $2.22
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- VANI 41.41
- CRBP 27.45
- Support Level
- VANI $1.06
- CRBP $5.76
- Resistance Level
- VANI $1.16
- CRBP $6.17
- Average True Range (ATR)
- VANI 0.04
- CRBP 0.39
- MACD
- VANI 0.01
- CRBP 0.03
- Stochastic Oscillator
- VANI 28.85
- CRBP 9.73
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.